Anum Ilyas, Hafeez-ud Din, Kulsoom Ilyas, Zunera Jahanzeb, Fibhaa Syed, Yagana Iqbal.
Comparison of efficacy of Moxifloxacin and Ceftriaxone in acute exacerbation of chronic obstructive pulmonary disease.
Ann Pak Inst Med Sci Jan ;19(1):40-3.

Objective: The aim was to compare the efficacy of Moxifloxacin and Ceftriaxone in acute exacerbation of the chronic obstructive pulmonary disease. Methodology: This randomized trial was conducted in the Pulmonology Department, PIMS, Islamabad between August 2018 to February 2019. Ethical approval was granted by the hospital ethics committee and patients were enrolled after written informed consent. Patients were screened from the OPD department and before randomization their sputum was collected over a 24-h period in strong sterile plastic (60 mL) bottle at room temperature. They were randomized equally into two treatment groups using a lottery method. Group A received Moxifloxacin 400 mg orally once daily for five days and group B received Ceftriaxone 1 g (IV infusion) once daily for five days. All the measurements (dyspnea grading, sputum volume, and character) were taken after 5 days of antibiotics therapy.  Results: The mean age was 60.79 ± 13.34 years in Moxifloxacin and 59.86 ± 12.72 years in the Ceftriaxone group. In Moxifloxacin group, there were 49(68.06%) male and 23(31.94%) females and in the Ceftriaxone group, there were 49(68%) males and 23(31.94%) female cases. In Moxifloxacin a total of 68(94.4%) cases recovered while 4 (5.6%) cases did not achieve efficacy whereas in the Ceftriaxone group 54 (75.0%) cases achieved efficacy and 18 (25.0%) were therapy failures. The efficacy of the oral Moxifloxacin group was significantly better than the oral Ceftriaxone group (p-value, < 0.05). Conclusion: The efficacy of Moxifloxacin was better than Ceftriaxone in acute exacerbation of chronic obstructive pulmonary disease.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com